



# Correction to: Efficacy of interatrial shunt devices: an opening window to acute pulmonary hypertensive crisis and chronic pulmonary arterial hypertension

Lifan Yang<sup>1,2</sup> · Lei Zhang<sup>1</sup> · Shasha Chen<sup>1</sup> · Mingfei Li<sup>1</sup> · Yuliang Long<sup>1</sup> · Wei Li<sup>1</sup> · Qi Jin<sup>1</sup> · Lihua Guan<sup>1</sup> · Daxin Zhou<sup>1</sup> · Junbo Ge<sup>1</sup>

Accepted: 12 July 2022 / Published online: 6 August 2022  
© Springer Science+Business Media, LLC, part of Springer Nature 2022

**Correction to:**  
**Journal of Thrombosis and Thrombolysis (2022) 54:123–131**  
<https://doi.org/10.1007/s11239-022-02635-3>

legend were as follows. These have been corrected with this erratum.

In the original version of the article, Fig. 3 and the legend mentioned was incorrectly. The correct Fig. 3 and

---

The original article can be found online at <https://doi.org/10.1007/s11239-022-02635-3>.


---

✉ Lihua Guan  
[guan.lihua@zs-hospital.sh.cn](mailto:guan.lihua@zs-hospital.sh.cn)

✉ Daxin Zhou  
[1194180219@qq.com](mailto:1194180219@qq.com)

<sup>1</sup> Division of Cardiology, Department of Cardiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital Affiliated to Fudan University, No 180, Fenglin Road, Shanghai 200032, China

<sup>2</sup> Shanghai Xuhui District Central Hospital, Shanghai, China



**Fig. 3** Interatrial shunt device implantation under DSA during the operation. **A** Atrial septal puncture (Beijing Synaptic Medical). **B** Balloon dilation (3–8 mm, Boston Scientific Corporation). **C** Interatrial shunt device implantation (ConFlow MedTech)

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.